Tetrous, Inc.

Media Contact:

Bradley Patt, PhD
Tetrous, Inc.
818-645-4081
bpatt@tetrous.com

Product Information:

John Bojanowski
Tetrous, Inc.
978-809-0374
jbojanowski@tetrous.com

TETROUS ANNOUNCES FIRST ENFIX RC™ SURGICAL CASES OUTSIDE THE UNITED STATES

Los Angeles, CA, July 13, 2023 — Tetrous Inc., a leading regenerative medicine company today announced that it has completed the first surgical cases in Australia using EnFix RC, a procedure-specific implant for rotator cuff repair that is specifically designed to address Enthesis Failure Syndrome. The procedures were performed successfully by Dr. Kenneth Cutbush, Dr. Ivan Popoff and Dr. Doron Sher.

“It is exciting that Tetrous is dedicated to developing new technology focused on healing the enthesis in rotator cuff surgery.  For far too long, the re-tear rates following rotator cuff surgery have remained high, especially for larger tears, with little to no attention given to post-operative healing at the tendon-bone interface.  The pre-clinical data is very compelling showing enthesis reformation at 12 weeks”, said Dr. Jerome Goldberg, M.B., B.S., F.R.A.C.S., F.A. Ortho A., Tetrous Clinical Advisory Board Member. “I am thrilled to be helping to bring this innovative technology to market in Australia,” he added.  The EnFix™ product line is being launched in Australia in partnership with Australian Biotechnologies.

Most studies show that 20% to 70% of rotator cuff repairs fail structurally. Inadequate tendon-to-bone ingrowth results in incomplete healing, gap formation and a high risk of re-tear. Tendon reattachment is a crucial clinical need, especially in larger tears because failure rates increase linearly with tear size. While most augmentation products have been designed as “overlays” to reinforce the tendon, EnFix RC changes the paradigm by enhancing healing at the enthesis where failure often occurs. This enhanced biologic repair at the interface between tendon and bone is a significant advance.

John Bojanowski, Tetrous Head of Sales and Marketing said,  “With first surgical cases in the U.S. two weeks ago, first cases in Australia last week and our official product launch at American Orthopaedic Society for Sports Medicine (AOSSM) annual meeting this week, things are moving fast.  It is great to see this game-changing technology become available to patients.”

Tetrous’ CTO, Andy Carter, PhD, added, “I have worked for many years successfully developing and delivering multiple products using demineralized bone fibers in spine. It’s rewarding to be able to deliver technology designed for use in sports medicine specific applications such as Rotator Cuff, ACL and Achilles procedures. EnFix RC for rotator cuff repair has performed magnificently and we expect to see widespread adoption in both the U.S. and Australia.”

The EnFix RC rotator cuff implant is made from proprietary demineralized cortical bone fibers.  Using Bone Textile™ technology to produce the implant yields long and strong bone fibers that promote cell wicking, cell adhesion and cell proliferation, while our FormLok™technology imparts shape retention to the device, even when immersed in liquid, as is regularly required for use in arthroscopic surgery.

###

About Tetrous, Inc.

Founded in 2019, Tetrous, Inc. utilizes next generation advanced technologies for enthesis repair in sports medicine applications. The first offerings in the EnFix family of products are EnFix RC and EnFix TAC for rotator cuff repair. Tetrous was conceived from technology developed for spine surgery. The Company is employing and expanding the technology for novel applications in sports medicine. Its core technology has been used in nearly 150,000 surgeries in spine applications. The demineralized bone fiber technology used in Tetrous products is licensed exclusively for use in sports medicine from TheraCell, an ISTO Biologics Company.  EnFix™, EnFix RC™ and EnFix TAC™ are trademarks of Tetrous, Inc.

For  more information visit www.tetrous.com and follow us on LinkedIn (www.linkedin.com/company/tetrous). 

About Australian Biotechnologies

Australian Biotechnologies manufactures and distributes life enhancing allograft tissue products for the Australian community. The business was founded in 2000 and is located in Frenchs Forest, New South Wales, Australia. With world class processing facilities, specially trained technical staff and strict quality procedures, the company is the first privately owned and operated tissue-processing facility in Australia. 

Bradley E. Patt, PhD

Dr. Patt is cofounder chairman of Tetrous.

Brad has over 40 years experience as an entrepreneur and executive manager. He has led several enterprises from start-up phase through rapid growth and merger and acquisitions.

Brad founded several high tech ventures since 1997. He is currently co-founder chairman and CEO of TheraCell and DermOQ. Previously he was co-founder, CEO and Chairman of Gamma Medica, Inc. Brad built Gamma to market leadership position in pre­clinical CT, PET, SPECT imaging and is inventor and developer of Molecular Breast Imaging for detecting otherwise occult breast cancer in dense­breasted women.

Brad is currently co­founder and Chairman of DermOQ, Inc., an oxygen skin care company; EVO Worldwide, Inc. and spin off Smart Breast Corp., medical diagnostic imaging systems companies; and Hyvida Brands, a functional beverage startup. He is a director of High Beauty a cannabis cosmetic company. Brad also founded and is a Director of Thrive Outside the Box, a nonprofit organization that identifies and develops areas of talent in individuals on the autistic spectrum.

Brad is an internationally recognized authority in the field of medical imaging with over one hundred scientific papers and presentations, several book chapters, and over 20 patents. He has been an invited speaker at several international conferences. He has held elected positions on the IEEE Nuclear Medicine Instrumentation Steering Committee (NMISC) and the IEEE Radiation Instrumentation Steering Committee (RISC), and was appointed to the Program Committee of the SPIE Medical applications of Penetrating Radiation, acting as Chairman of the Penetrating Radiation Work Group for 2003 and 2004. Dr. Patt is a consultant to the National Institutes of Health and the recipient of over $15 million dollars of grant awards as Principal Investigator from the National Institutes of Health, The United States Department of Energy and NASA.

Bradley E. Patt, PhD

Dr. Patt is cofounder chairman of Tetrous. Brad has over 40 years experience as an entrepreneur and executive manager. He has led several enterprises from start-up phase through rapid growth and merger and acquisitions. Brad founded several high tech ventures since 1997. He is currently co-founder chairman and CEO of TheraCell and DermOQ. Previously he was co-founder, CEO and Chairman of Gamma Medica, Inc. Brad built Gamma to market leadership position in pre­clinical CT, PET, SPECT imaging and is inventor and developer of Molecular Breast Imaging for detecting otherwise occult breast cancer in dense­breasted women. Brad is currently co­founder and Chairman of DermOQ, Inc., an oxygen skin care company; EVO Worldwide, Inc. and spin off Smart Breast Corp., medical diagnostic imaging systems companies; and Hyvida Brands, a functional beverage startup. He is a director of High Beauty a cannabis cosmetic company. Brad also founded and is a Director of Thrive Outside the Box, a nonprofit organization that identifies and develops areas of talent in individuals on the autistic spectrum. Brad is an internationally recognized authority in the field of medical imaging with over one hundred scientific papers and presentations, several book chapters, and over 20 patents. He has been an invited speaker at several international conferences. He has held elected positions on the IEEE Nuclear Medicine Instrumentation Steering Committee (NMISC) and the IEEE Radiation Instrumentation Steering Committee (RISC), and was appointed to the Program Committee of the SPIE Medical applications of Penetrating Radiation, acting as Chairman of the Penetrating Radiation Work Group for 2003 and 2004. Dr. Patt is a consultant to the National Institutes of Health and the recipient of over $15 million dollars of grant awards as Principal Investigator from the National Institutes of Health, The United States Department of Energy and NASA.